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Background: There is growing evidence supporting the role of inflammation in aneurysmal subarachnoid hemorrhage
(aSAH) pathophysiology and it is of great interest to elucidate which immune mechanisms are involved.
Methods: 12 aSAH patients and 28 healthy controls were enrolled prospectively. We assessed leukocytes
subpopulations and their activation status by flow cytometry in cerebrospinal fluid (CSF) and peripheral blood (PB) of
SAH patients at the same time and in PB of controls.
Results: Monocytes and neutrophils were activated in CSF of aSAH patients. The percentage of CD14++CD16+
monocytes were higher in CSF than in PB of aSAH patients, and were also increased in PB of aSAH patients compared
with controls. An enhanced expression of CD69 was shown in CSF neutrophils compared with PB in aSAH patients. PB
of aSAH patients showed lower percentage of total lymphocytes compared with controls PB. Additionally, lymphocytes
were activated in CSF and PB of aSAH patients. CD4+ and CD8+ T cells had a decreased expression on CD3 and higher
levels of CD69 in CSF compared with PB in aSAH patients. Moreover, PB CD4+ and CD8+ T cells of aSAH patients were
activated compared with controls. Additionally, CD28 expression was decreased on CSF T lymphocytes.
Conclusions: Our data suggest an important recruitment of leukocytes to the site of injury in aSAH as well as an
increased activation at this level. Overall, these results indicate that aSAH probably stimulates both the innate and
adaptive immune responses.
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Flow cytometryBackground
Aneurismal subarachnoid hemorrhage (aSAH) is an acute
cerebrovascular event which can have catastrophic impact
not only on the central nervous system but also on several
other organs (Hinson and Sheth 2012; Mashaly and
Provencio 2008; Schuiling et al. 2005; Stevens and Nyquist
2007). Despite great advances in neuroscience that had
occurred in the last decades, morbidity and mortality re-
main very high. There is growing evidence for the role of* Correspondence: sofiagrille@gmail.com
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in any medium, provided the original work is pinflammatory response in the pathophysiology of main
aSAH complications (intracranial hypertension, rebleeding
and vasospasm) (Miller et al. 2014); (McMahon et al.
2013); (Provencio and Vora 2005); (Provencio 2013).
It has been postulated that the extravasated blood in
the subarachnoid space following aneurysm rupture is
responsible for a cascade of immune reactions involving
the release of various vasoactive and pro-inflammatory
factors which contributes to early and delayed brain in-
jury (Caner et al. 2012; Edvinsson and Povlsen 2011;
Fujii et al. 2013; Lindgren et al. 2014; Mehta et al. 2013;
Provencio 2013; Wan et al. 2014). Many results strongly
suggest that aSAH elicits an immunological process that
includes both cellular and humoral immunity (Chen et al.
2014; Plog et al. 2014; J J Provencio et al. 2010; Provencioan Open Access article distributed under the terms of the Creative Commons
g/licenses/by/4.0), which permits unrestricted use, distribution, and reproduction
roperly credited.






Age (median and range) 48.5 (34–67) 45 (25–76) 0.62 (NS)
Gender. Male: female 0.33:1 0.1:1 0.46 (NS)












Vasospasm n (%) 5 (42)
Mortality n* (%) 7/12 (58)
*In the intensive care unit.
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has been demonstrated in both experimental and clinical
models of SAH (Schneider et al. 2012; Sercombe et al.
2002). Recent studies showed a pro-inflammatory milieu
in serum and cerebrospinal fluid (CSF) after the
hemorrhagic event (Schneider et al. 2012). Pro-
inflammatory cytokines such as interleukin-6 (IL-6), IL-1,
TNF-α and complement have been detected in CSF of
aSAH patients indicating that they might be involved in
the pathogenesis of vasospasm (Dhar and Diringer 2008;
Dumont et al. 2003; Fassbender et al. 2001; Greenhalgh
et al. 2012; Hendryk et al. 2004; Kwon and Jeon 2001;
Sarrafzadeh et al. 2010; Sercombe et al. 2002; Xie et al.
2013; You et al. 2013; Zhou et al. 2007). Little is known
about the role of adaptive immune system in aSAH. Nec-
ropsies and studies in animals of the blood vessels and
walls of ruptured aneurysms have found B and T lympho-
cyte infiltration in the wall of aneurysm tissue (Chyatte
et al. 1999; Hughes and Schianchi 1978). However, analysis
of T and B cell subsets in CSF and peripheral blood (PB)
in aSAH patients is not yet available.
In this report, we studied and compared in paired
samples of CSF and PB, granulocytes, monocytes and
lymphocytes subsets and their activation status in twelve
aSAH patients and controls. These findings may contrib-
ute to the knowledge of the immunopathological mecha-
nisms underlying early and late brain injury in aSAH
and may promote the development of novels treatment
strategies (Chen et al. 2014; Cheng et al. 2014; Echigo
et al. 2012; Muroi et al. 2014; Satoh et al. 2014; Uekawa
et al. 2014; Zhang et al. 2014).
Results
Patient characteristics
Clinical and demographic characteristics of the twelve
enrolled patients and controls are shown in Table 1. 75%
(n = 9) of patients presented with Hunt and Hess (HH)
grade of 4 or above and the majority had Fisher grade 3
SAH (n = 7). CSF and PB samples were obtained within
6 days from bleeding (day 0). Five patients (42%) devel-
oped vasospasm and seven died (58%).
CSF white cell count
We have measured the absolute number of white cells in
CSF of SAH patients prior flow cytometry analysis. All
CSF samples contained an increase and sufficient num-
ber of leukocytes for flow cytometry analysis. We found
an absolute white cell count mean of 745,4×106/l (range
100–3100×106/l).
Monocytes and neutrophils were activated in CSF of
aSAH patients
As shown in Figure 1A the percentage of CD14++CD16+
monocytes in CSF (median 34%) were higher than those inPB of aSAH patients (median 9.4%). Also, CD14++CD16+
monocytes were lower in PB of aSAH patients compared
with controls (median 21.4%; p = 0.010). No differences
were observed in total monocytes percentage.
No differences were observed in neutrophils percent-
age between groups. However, the proportion of neutro-
phils expressing the early activation marker CD69 was
higher in CSF than in PB in aSAH patients (Figure 1B).
Lymphocytes subsets in CSF and PB of aSAH patients and
controls
The percentage of CD4+ T cell, CD8+ T cells, B and NK
cells of total lymphocytes were similar between CSF and
PB of aSAH patients. PB of aSAH patients showed lower
percentage of total lymphocytes compared with controls.
In addition, differences in the distribution of lymphocyte
subpopulations were observed. As shown in Figure 2, PB
of aSAH patients showed a higher percentage of CD4+ T
cells and a lower percentage of NK cells compared with
controls. Additionally, the percentage of B cells was
slightly lower in CSF compared with PB of aSAH patients.
Lymphocytes were activated in CSF and PB of aSAH patients
CD4+ and CD8+ T cells showed an activated profile
(Figure 3). As shown in Figure 3A and B, CD4+ and CD8+
T cells had a decreased expression on CD3 in CSF com-
pared with PB in aSAH patients. We observed almost a 1,8
fold decrease in CD3 expression on CD4+ T cells and a
twofold decrease on CD8+ T cells in CSF compared with
PB sampling at the same time. Additionally, the ratio of
Figure 1 Monocytes and neutrophils. A) Percentages of total monocytes and CD14++CD16+ monocytes in CSF and PB of aSAH patients and in
PB of controls. Data shown are median ± standard error. B) CD69 expression on neutrophils in CSF and PB of aSAH patients and in PB of controls.
Data shown are median of CD69 mean fluorescence intensity (MFI) on neutrophils ± standard error.
Figure 2 Lymphocytes subsets. Percentages of CD4+ T cells, CD8+ T cells, NK cells and B cells lymphocytes of total lymphocytes in CSF and PB of
aSAH patients and in PB of controls. Data shown are median ± standard error.
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Figure 3 Activation pattern in CD4+ and CD8+ T cells. A) CD3 mean fluorescence intensity (MFI) on CD4+ T cells in PB and CSF of aSAH patients.
Lines indicate samples from the same patient on the same time. B) CD3 MFI on CD8+ T cells in PB and CSF of aSAH patients. Lines indicate
samples from the same patient on the same time. C) Ratio of CD4+ CD69+ T cells/CD4+ T cells and CD8+ CD69+ T cells/CD8+ T cells. Data shown
are median ± standard error.
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and activated CD8+/ Total CD8+ T cells (CD8+CD69+/
CD8+) were increased in CSF compared with PB in aSAH
patients (Figure 3C). Moreover, PB CD4+ and CD8+ T cells
of aSAH patients were activated compared with controls.
As shown in Figure 3C, CD4+CD69+/CD4+ and CD8+
CD69+/CD8 were increased in aSAH patients compared
with controls.
CD28 expression was decreased on CSF T lymphocytes
We also studied the expression of T-cell co-stimulatory
molecule CD28 on CD4+ and CD8+ T cells. As shown in
Figure 4, CSF CD4+ and CD8+ T cells express lower
levels of CD28 than PB CD4+ and CD8+ T cells in aSAH
patients. We observed a twofold decrease in CD28Figure 4 CD28 expression on CD4+ and CD8+ T cells. A) CD28 mean fluor
Lines indicate samples from the same patient on the same time. B) CD28 M
samples from the same patient on the same time.expression on CD4+ T cells and a 2.7 fold decrease on
CD8+ T cells in CSF compared with PB sampling at the
same time. No differences were observed in CD28 ex-
pression of CD8+ T cells between PB of aSAH patients
and controls.
In five patients we took 2 CSF samples in different
moments (1 to 3 and 4 to 6 days from bleeding). No
differences among any subtype of immune cell subpop-
ulations (including activation status) were evidenced
(data not shown). Five patients had an EVD and a LD
inserted during the first days after bleeding. CSF samples
from both places were taken in two different moments
(48 hours interval) simultaneously. No differences among
any subtype of immune cell subpopulations (including ac-
tivation status) were evidenced (data not shown).escence intensity (MFI) on CD4+T cells of PB and CSF of aSAH patients.
FI on CD8+T cells on PB and CSF of aSAH patients. Lines indicate
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Aneurysm rupture provokes a substantial local and sys-
temic inflammatory response and there is convincing
evidence that inflammation plays a critical role in early
and delayed brain injury contributing to the poor out-
come caused by SAH (Chou et al. 2012; Rodríguez-
Rodríguez et al. 2014; Sercombe et al. 2002).
Blood cells, cytokines and complement in the subarach-
noid space following aneurysm rupture seem to play a
major role triggering inflammatory reactions. Cytokines
can trigger strong pro and anti-inflammatory effects. In-
flammatory cytokines in CSF, such as IL-6, IL-8, IL-1 and
TNF-α were shown to be elevated in aSAH patients, with
a greater increase in patients with unfavourable outcome
(Chou et al. 2012; Fassbender et al. 2000; Gruber et al.
2000; Hirashima et al. 1997; Nakahara et al. 2009;
Provencio 2013; Sarrafzadeh et al. 2010).
This highlights the involvement of innate immunity in
SAH. In addition, several reports have linked CSF cy-
tokines increase with the generation of delayed brain
injury associated with vasospasm, one of the most com-
mon and feared complications of aSAH (Bowman et al.
2006; Hendryk et al. 2004; Ni et al. 2011; Provencio 2013;
Wang et al. 2007; You et al. 2013)
In this report we show an activated profile in innate
immune cells (monocytes and neutrophils). We found a
marked increase in the percentage of CD14++CD16+
monocytes in CSF compared with PB and a decreased in
PB of aSAH patients compared with controls. Human
blood monocytes are heterogeneous and conventionally
subdivided into three subsets based on CD16 and CD14
expression (CD14++CD16−, CD14+CD16++, CD14++CD16+
monocytes) (Wong et al. 2012). It is known that CD16+ ex-
pression in monocytes/ macrophages indicates activation of
these cells and it has been suggested that they have a proin-
flammatory function based on higher expression of pro-
inflammatory cytokines and higher potency in antigen
presentation (Ziegler-Heitbrock 2007). Belge et al. found
that after in vitro stimulation with LPS, CD16+ monocytes
produced high levels of TNF-α (pro-inflammatory cytokine)
and low levels of IL-10 (anti-inflammatory cytokines) (Belge
et al. 2002). Many reports showed that TNF-α was in-
creased in CSF of aSAH patients, particularly in patients
with unfavorable outcomes (Chou et al. 2012; Fassbender
et al. 2000; Kwon and Jeon 2001; Mathiesen et al. 1997).
Although a variety of cell types are known to express TNF-
α, CD16+ monocytes could be an important source of TNF-
α in CSF of aSAH patients. Additionally, it has been
published that CD16+ monocytes show a higher level of
HLA-DR (Passlick et al. 1989), and this would predict a
higher antigen presenting cell (APC) activity in these cells.
In vitro studies found that CD16+ monocytes was three
times more potent APC when compared with CD16−
monocytes (Grage-Griebenow et al. 2001; Zawada et al.2012). Our results evidence that CD14++CD16+ monocytes
infiltrate the CSF of aSAH patients suggesting that they may
play an important role in the pathogenesis of this disease.
To study the activation status of neutrophils, we mea-
sured the CD69 surface activation marker (very early acti-
vation antigen) expression. We found an increased (CD69
expression) in CSF neutrophils compared with PB of
aSAH patients, suggesting an increased activation status
in CSF neutrophils. Activated neutrophils could not only
participate in subarachnoid blood clearance, but also could
be an important source of cytokines in CSF of aSAH
patients (Cassatella 2013).
The increased proportion of CD69+ neutrophils and
CD14++CD16+ monocytes probably indicates an ongoing
systemic inflammation and a stimulation of innate im-
munity in aSAH patients.
On the other hand, we also studied and found interesting
data about adaptive immune cells. T lymphocytes are cen-
tral in developing a sustained inflammatory response, and
they are source of cytokines that may play a role in early
and delayed brain injury after aSAH. Although no differ-
ence were found in percentage of CD4+ and CD8+ T cells
between CSF and PB of aSAH patients and controls, CSF
CD4+ and CD8+ T cells showed an increased activation sta-
tus determined by decreased expression of CD3, CD28 and
an increased expression on CD69. Additionally, PB CD4+
and CD8+ T cells were more activated compared with con-
trols, assessed by CD69 expression. CD3 downregulation
from the cell surface is normally associated with in vitro
and in vivo T-cell activation (Comar et al., 2005; Sullivan
and Coscoy, 2008). We also study the expression of T-cell
co-stimulatory molecule CD28 on CD4+ and CD8+ T cells.
We found that CSF CD4+ and CD8+ T cells express lower
levels of CD28 than PB CD4+ and CD8+ T cells in aSAH
patients. CD28 is the only B7 receptor constitutively
expressed on naive T cells and provides co-stimulatory sig-
nals, which are required for T cell activation. Stimulation
through CD28 and T Cell Receptor (TCR) can provide a
potent co-stimulatory signal to T cells for the production
of various interleukins. Human T-cells that have under-
gone repeated cycles of antigen-driven proliferation de-
velop a series of phenotypic and functional changes,
including the disappearance of cell-surface CD28. Hence,
finding a lower expression of CD28 or CD4 +CD28null
cells suggest the presence of an activation status and a
chronic adaptive immune response (Studer et al. 2008;
Vallejo et al. 2004; Vallejo 2005; van Leeuwen et al.
2004). Additionally, it has been reported that TNF-α
downregulated the expression of CD28 on T cells (Bryl
et al. 2001). This could explain the finding of the increased
CD14++CD16+ monocytes number and the increased level
of TNF-α previously reported in these patients.
Adaptive immunity has been little studied in the context
of aSAH. Mathiesen et al. in 1993 reported that IL-2
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SAH patients suggesting the role of adaptive immune re-
sponse in the SAH pathogenesis (Mathiesen et al. 1993).
Adaptive immunity has been study in ischemic stroke, in
ischemia-reperfusion brain injury, and other neurologic
disease (Brait et al. 2012; Cepok et al. 2001). Following an
ischemic stroke, T cells become activated, infiltrate the
brain and release cytokines and reactive oxygen species
that probably contribute to brain injury (reviewed in (Brait
et al. 2012)). Additionally, there is evidence that T cells ac-
cumulate in the post-ischemic brain within few hours after
reperfusion (reviewed in (Brait et al. 2012)). As far as we
know, this is the first report that evidences an early activa-
tion profile in CSF CD4+ and CD8+ T cells in aSAH pa-
tients, suggesting the participation of adaptive immune
response in the immunopathogenesis of this disease.
We also found that the percentage of NK and B cells
in PB of aSAH patients were lower compared with con-
trols, but without an increase in CSF compared with PB
of aSAH patients. In other disease models, for example
in ischemic stroke, it has been observed that the levels
of lymphocytes and other immune effectors in circula-
tion are reduced, possibly as an endogenous protective
mechanism (Liesz et al. 2009; Martin et al. 2008). Also,
there are a reduced number of T cells and other immune
cells in spleen, thymus and lymph nodes (reviewed in
(Brait et al. 2012)). Some authors postulate that this
determines a “stroke-induced immunodeficiency syn-
drome” that may contribute to the increased incidence
of infections observed in these patients. Urra et al. re-
ported an increased apoptosis rate and a reduction in PB
levels of CD4+ and CD8+ T cells, T regulatory cells and
B cells following ischemic stroke (Urra et al. 2009).
There is increasing evidence that an impairment of cel-
lular immune function after acute central nervous sys-
tem injury, such as stroke and traumatic brain injury
represents a risk factor for infections (Chamorro et al.
2007; Klehmet et al. 2009; Woiciechowsky et al. 1998).
Additionally, Sarrafzadeh et al. reported a SAH-induced
immunodepression and found T-lymphopenia and a de-
creased monocyte human leukocyte antigen-DR expres-
sion on PB. Immunodepression was associated with a
high incidence of pneumonia (Sarrafzadeh et al. 2011).
In that way, we may speculate that the slightly reduction
in the percentage of PB NK and B cells could be due to
an increase in apoptosis or a differentiation to other sub-
population probably contributing to the immunosup-
pression observed in this patients.
Limitation of the study
The main limitation of our pilot study is the small number
of enrolled patients. Thus, we decided not to attempt a
detailed statistical analysis. Additionally, considering the
small sample of patients and the fact that most of themhave a severe aSAH (Table 1) with high mortality our re-
sults should be interpreted with caution and could not be
extrapolated to patients suffering from less severe disease.
Further investigation is warranted.
Additionally, in our hospital EVDs and/or LDs are
inserted in the acute period (within the first week from
bleeding) mainly in patients complicated with hydro-
cephalus, Fisher III or IV (increased risk of vasospasm)
and/or GCS < 9 (poor clinical grade with greater risk of
vasospasm and intracranial hypertension). The enroll-
ment of a significant number of mild cases (HH 1–3
and/or Fisher 2) would only be achieved if new and con-
vincing data arises in the near future from ongoing trials
(Early drain trial is not enrolling Fisher 1 patients).
Although we did not find any differences among im-
mune cells subpopulations and their activation status in
two different moments within the first week since
aneurysm rupture (day 0), our approach only covers a
very short period of time and changes are still possible
considering that the inflammatory response is essentially
a dynamic process.
Finally, the risk of infection represents a clear obstacle
to extend the sampling period at our institution (the in-
fection rate increases substantially when an EVD stays
longer than 5 days and a LD stays longer than 7 days).
The introduction of new coated catheters could help us
to overcome this critical barrier.
Conclusion
The results presented here suggest that effectors of both
innate and adaptive immune response may play a role in
the pathogenesis of severe aSAH. We found not only a
recruitment in CSF and activation of monocytes and
neutrophils (innate immune response effectors), but also
an activation of CD4+ and CD8+ T cells (adaptive im-
mune response effectors). More research and a greater
number of patients evaluated are needed to gain greater
understanding in the immunopathogenesis of aSAH and




aSAH patients and control subjects were recruited pro-
spectively. Twelve patients (9 women and 3 men) with a
median age of 48.5 years (range 34–67 years) with aSAH
were included in the study. Twenty eight healthy control
subjects (asymptomatic, without any major vascular risk
factor or acute or chronic inflammatory/infection dis-
ease) were included with a median age of 45 (range 25–
76 years). There were no significant differences in age
between aSAH and control group (Table 1).
Considering recent published data (Kowarik et al.
2014) we decided not to perform CSF flow cytometry
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cells main subtypes (CD4+ T cells, CD8+ T cells, CD4/
CD8 ratio, monocytes, B cells, plasmablasts and NK
cells) in normal CSF from symptomatic controls (head-
ache and paresthesia of unspecific origin) as a reference
are reported.
Depending on hospital availability, the aneurysm diag-
nostic technique were digital subtraction angiography
(DSA) or computed tomography angiography (CTA).
Patients with traumatic SAH, pregnancy, intracranial
malignancies, or infectious meningitis were excluded.
All SAH patients underwent transcranial doppler (TCD)
monitoring for vasospasm screening from day 1 to 14.
Vasospasm in the middle cerebral artery (MCA) and an-
terior cerebral artery (ACA) was defined by a mean cere-
bral blood flow velocity (mCBFV) exceeding 120 cm/s and
three times the mean flow velocity (FV) of the ipsilateral
extracranial internal carotid artery (eICA) (Lindegaard
Ratio > 3). Basilar artery (BA) vasospasm was defined
whenever the mCBFV was higher than 85 cm/s and two
times the mean FV of the extracranial vertebral artery
(eVA)(Soustiel Ratio > 2).
Sampling
CSF and PB samples were collected within 6 days from
bleeding (median 3 days, range 1–6 days). CSF samples
were acquired from patients who had an external ven-
tricular drain (EVD) and/or a lumbar drain (LD) placed
for clinical indications. At the same time, 1 ml of CSF
and 2 ml of PB were collected from aSAH patients. Au-
tomated CSF leukocyte counts were obtained on ABX
micros 60 (Horiba, Montpellier, France). Samples were
examined by 4-colour flow cytometry within 30 min
from sampling. Additionally, 2 ml of PB were collected
from controls.
Leukocyte subsets in cerebrospinal fluid and peripheral blood
Analyses of leukocyte subsets were conducted by flow cy-
tometry on CSF and PB taken from patients and controls.
Cells were washed twice with phosphate-buffered saline
and immunostained for 15 min at room temperature with
the following panel of antibodies: PE-Cy5.5-conjugated
anti-CD3, APC-conjugated anti-CD3, APC-conjugated
anti-CD4, APC-conjugated anti-CD14, FITC-conjugated
anti-CD4, FITC-conjugated anti-CD8, APC- conjugated
anti-CD8, PE-conjugated anti-CD69, PE-conjugated anti-
CD28, FITC-conjugated anti-CD56, PE-conjugated anti-
CD16, PERCP-conjugated anti-CD19, FITC-conjugated
anti-CD16, FITC-conjugated CD11b (all reagents from
BD Pharmingen, San Diego, USA). Optimal antibody con-
centrations were previously defined by titration. After in-
cubation, red blood cells were lysed with FACS lysing
solution (Becton-Dickinson, San Diego, CA). The cells
were washed and suspended in phosphate-buffered saline.Flow cytometry data was collected on a FACS Calibur Flow
cytometer equipped with two lasers (Becton–Dickinson,
Oxford, UK). For data acquisition and analysis CellQuest
software (Becton–Dickinson) and Infinicyt™ (Cytognos,
Spain) were used. Gating strategy: neutrophils were gated
by side scatter and CD11b. Monocytes were gated by side
scatter and CD14, subsequently CD16 and CD69 were
evaluated. T cells were gated by side scatter and CD3 and
subsequently by CD8 or CD4. Then, CD69 and CD28 ex-
pression were measured. B cells were gated by side scatter
and CD19 expression without CD3 expression. NK were
gated by side scatter and CD56 or CD16 expression and
different subsets were measured.
Statistical analysis
Statistical analysis was performed using SPSS (Chicago,
IL, USA). Descriptive statistics were used and measures
of central tendency and dispersion were calculated.
Ethical consideration
Informed consent was obtained from the patients or rel-
atives and controls enrolled in this study. The protocol
was approved by the Institutional Review Board of de
Hospital de Clínicas, Montevideo, Uruguay, in accord-
ance with the Declaration of Helsinki.
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